Nuclear Export Is Required for Degradation of Endogenous p53 by MDM2 and Human Papillomavirus E6

REFERENCES

• Barak, Y., E. Gottlieb, T. Juven-Gershon, and M. Oren 1994. Regulation of mdm2 expression by p53: alternative promoters produce transcripts with nonidentical translation potential. Genes Dev. 8: 1739–1749.
   PubMed Web of Science ®Google Scholar
• Barak, Y., T. Juven, R. Haffner, and M. Oren 1993. mdm2 expression is induced by wild type p53 activity. EMBO J. 12: 461–468.
   PubMed Web of Science ®Google Scholar
• Bueso-Ramos, C. E., Y. Yang, E. deLeon, P. McCown, S. A. Stass, and M. Albitar 1993. The human MDM-2 oncogene is overexpressed in leukemias. Blood 82: 2617–2623.
   PubMed Web of Science ®Google Scholar
• Chen, J., J. Lin, and A. J. Levine 1995. Regulation of transcription functions of the p53 tumor suppressor by the mdm-2 oncogene. Mol. Med. 1: 142–152.
   PubMedGoogle Scholar
• Chen, J., V. Marechal, and A. J. Levine 1993. Mapping of the p53 and mdm-2 interaction domains. Mol. Cell. Biol. 13: 4107–4114.
   PubMed Web of Science ®Google Scholar
• Chen, J., X. Wu, J. Lin, and A. J. Levine 1996. mdm-2 inhibits the G1 arrest and apoptosis functions of the p53 tumor suppressor protein. Mol. Cell. Biol. 16: 2445–2452.
   PubMed Web of Science ®Google Scholar
• Cordon-Cardo, C., E. Latres, M. Drobnjak, M. R. Oliva, D. Pollack, J. M. Woodruff, M. F. Brennan, V. Marechal, J. Chen, and A. J. Levine 1994. Molecular abnormalities of mdm-2 and p53 genes in adult soft tissue sarcomas. Cancer Res. 54: 794–799.
   PubMed Web of Science ®Google Scholar
• El-Deiry, W. S., T. Tokino, V. E. Velculescu, D. B. Levy, R. Parsons, J. M. Trent, D. Lin, W. E. Mercer, K. W. Kinzler, and B. Vogelstein 1993. WAF1, a potential mediator of p53 tumor suppression. Cell 75: 817–825.
   PubMed Web of Science ®Google Scholar
• Fakharzadeh, S. S., S. P. Trusko, and D. L. George 1991. Tumorigenic potential associated with enhanced expression of a gene that is amplified in a mouse tumor cell line. EMBO J. 10: 1565–1569.
   PubMed Web of Science ®Google Scholar
• Finlay, C. A. 1993. The mdm-2 oncogene can overcome wild-type p53 suppression of transformed cell growth. Mol. Cell. Biol. 13: 301–306.
   PubMed Web of Science ®Google Scholar
• Fornerod, M., M. Ohno, M. Yoshida, and I. W. Mattaj 1997. CRM1 is an export receptor for leucine-rich nuclear export signals. Cell 90: 1051–1060.
   PubMed Web of Science ®Google Scholar
• Freedman, D. A., C. B. Epstein, J. C. Roth, and A. J. Levine 1997. A genetic approach to mapping the p53 binding site in the MDM2 protein. Mol. Med. 3: 248–259.
   PubMed Web of Science ®Google Scholar
• Fukuda, M., S. Asano, T. Nakamura, M. Adachi, M. Yoshida, M. Yanagida, and E. Nishida 1997. CRM1 is responsible for intracellular transport mediated by the nuclear export signal. Nature 390: 308–311.
   PubMed Web of Science ®Google Scholar
• Hatakeyama, S., J. P. Jensen, and A. M. Weissman 1997. Subcellular localization and ubiquitin-conjugating enzyme (E2) interactions of mammalian HECT family ubiquitin protein ligases. J. Biol. Chem. 272: 15085–15092.
   PubMedGoogle Scholar
• Haupt, Y., R. Maya, A. Kazaz, and M. Oren 1997. Mdm2 promotes the rapid degradation of p53. Nature 387: 296–299.
   PubMed Web of Science ®Google Scholar
• Kastan, M. B., Q. Zhan, W. S. El-Deiry, F. Carrier, T. Jacks, W. V. Walsh, B. S. Plunkett, B. Vogelstein, Fornace A. J., Jr. 1992. A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasia. Cell 71: 587–597.
   PubMed Web of Science ®Google Scholar
• Kubbutat, M. H. G., S. N. Jones, and K. H. Vousden 1997. Regulation of p53 stability by Mdm2. Nature 387: 299–303.
   PubMed Web of Science ®Google Scholar
• Ladanyi, M., C. Cha, R. Lewis, S. C. Jhanwar, A. G. Huvos, and J. H. Healey 1993. MDM2 gene amplification in metastatic osteosarcoma. Cancer Res. 53: 16–18.
   PubMed Web of Science ®Google Scholar
• Leach, F. S., T. Tokino, P. Meltzer, M. Burrell, J. D. Oliner, S. Smith, D. E. Hill, D. Sidransky, K. W. Kinzler, and B. Vogelstein 1993. p53 mutation and MDM2 amplification in human soft tissue sarcomas. Cancer Res. 53: 2231–2234.
   PubMed Web of Science ®Google Scholar
• Levine, A. J. 1997. p53, the cellular gatekeeper for growth and division. Cell 88: 323–331.
   PubMed Web of Science ®Google Scholar
• Liang, X. H., M. Volkmann, R. Klein, B. Herman, and S. J. Lockett 1993. Co-localization of the tumor-suppressor protein p53 and human papillomavirus E6 protein in human cervical carcinoma cell lines. Oncogene 8: 2645–2652.
   PubMedGoogle Scholar
• Lin, J., J. Chen, B. Elenbaas, and A. J. Levine 1994. Several hydrophobic amino acids in the p53 amino-terminal domain are required for transcriptional activation, binding to mdm-2 and the adenovirus 5 E1B 55-kD protein. Genes Dev. 8: 1235–1246.
   PubMed Web of Science ®Google Scholar
• Lu, H., and A. J. Levine 1995. Human TAFII31 protein is a transcriptional coactivator of the p53 protein. Proc. Natl. Acad. Sci. USA 92: 5154–5158.
   PubMedGoogle Scholar
• Maki, C. G., J. M. Huibregtse, and P. M. Howley 1996. In vivo ubiquitination and proteasome-mediated degradation of p53. Cancer Res. 56: 2649–2654.
   PubMed Web of Science ®Google Scholar
• Maltzman, W., and L. Czyzyk 1984. UV irradiation stimulates levels of p53 cellular tumor antigen in nontransformed mouse cells. Mol. Cell. Biol. 4: 1689–1694.
   PubMed Web of Science ®Google Scholar
• Miyashita, T., and J. C. Reed 1995. Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. Cell 80: 293–299.
   PubMed Web of Science ®Google Scholar
• Montes de Oca Luna, R., D. S. Wagner, and G. Lozano 1995. Rescue of early embryonic lethality in mdm2-deficient mice by deletion of p53. Nature 378: 203–206.
   PubMed Web of Science ®Google Scholar
• Munger, K., W. C. Phelps, V. Bubb, P. M. Howley, and R. Schlegel 1989. The E6 and E7 genes of the human papillomavirus type 16 together are necessary and sufficient for transformation of primary human keratinocytes. J. Virol. 63: 4417–4421.
   PubMed Web of Science ®Google Scholar
• Okamoto, K., and D. Beach 1994. Cyclin G is a transcriptional target of the p53 tumor suppressor protein. EMBO J. 13: 4816–4822.
   PubMed Web of Science ®Google Scholar
• Oliner, J. D., K. W. Kinzler, P. S. Meltzer, D. L. George, and B. Vogelstein 1992. Amplification of a gene encoding a p53-associated protein in human sarcomas. Nature 358: 80–83.
   PubMed Web of Science ®Google Scholar
• Oliner, J. D., J. A. Pietenpol, S. Thiagalingam, J. Gyuris, K. W. Kinzler, and B. Vogelstein 1993. Oncoprotein MDM2 conceals the activation domain of tumour suppressor p53. Nature 362: 857–860.
   PubMed Web of Science ®Google Scholar
• Olson, D. C., V. Marechal, J. Momand, J. Chen, C. Romocki, and A. J. Levine 1993. Identification and characterization of multiple mdm2 proteins and mdm2-p53 protein complexes. Oncogene 8: 2353–2360.
   PubMed Web of Science ®Google Scholar
• Ossareh-Nazari, B., F. Bachelerie, and C. Dargemont 1997. Evidence for a role of CRM1 in signal-mediated nuclear protein export. Science 278: 141–144.
   PubMed Web of Science ®Google Scholar
• Palmer, A., A. J. Rivett, S. Thomson, K. B. Hendil, G. W. Butcher, G. Fuertes, and E. Knecht 1996. Subpopulations of proteasomes in rat liver nuclei, microsomes and cytosol. Biochem. J. 316: 401–407.
   PubMed Web of Science ®Google Scholar
• Reifenberger, G., L. Liu, K. Ichimura, E. E. Schmidt, and V. P. Collins 1993. Amplification and overexpression of the MDM2 gene in a subset of human malignant gliomas without p53 mutations. Cancer Res. 53: 2736–2739.
   PubMed Web of Science ®Google Scholar
• Rivett, A. J. 1998. Intracellular distribution of proteasomes. Curr. Opin. Immunol. 10: 110–114.
   PubMedGoogle Scholar
• Roth, J., M. Dobbelstein, D. A. Freedman, T. Shenk, and A. J. Levine 1998. Nucleo-cytoplasmic shuttling of the hdm2 oncoprotein regulates the levels of the p53 protein via a pathway used by the human immunodeficiency virus rev protein. EMBO J. 17: 554–564.
   PubMed Web of Science ®Google Scholar
• Scheffner, M., B. A. Werness, J. M. Huibregtse, A. J. Levine, and P. M. Howley 1990. The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell 63: 1129–1136.
   PubMed Web of Science ®Google Scholar
• Shieh, S.-Y., M. Ikeda, Y. Taya, and C. Prives 1997. DNA damage-induced phosphorylation of p53 alleviates inhibition by MDM2. Cell 91: 325–334.
   PubMed Web of Science ®Google Scholar
• Stommel, J., and G. Wahl. Personal communication.
   Google Scholar
• Strack, P. R., E. F. Wajnberg, L. Waxman, and J. M. Fagan 1992. Comparison of the multicatalytic proteinases isolated from the nucleus and cytoplasm of chicken red blood cells. Int. J. Biochem. 24: 887–895.
   PubMedGoogle Scholar
• Thut, C. J., J.-L. Chen, R. Klemm, and R. Tjian 1995. p53 transcriptional activation mediated by coactivators TAFII40 and TAFII60. Science 267: 100–104.
   PubMedGoogle Scholar
• Thut, C. J., J. A. Goodrich, and R. Tjian 1997. Repression of p53-mediated transcription by MDM2: a dual mechanism. Genes Dev. 11: 1974–1986.
   PubMedGoogle Scholar
• Werness, B. A., A. J. Levine, and P. M. Howley 1990. Association of human papillomavirus types 16 and 18 E6 proteins with p53. Science 248: 76–79.
   PubMed Web of Science ®Google Scholar
• Wu, L., and A. J. Levine 1997. Differential regulation of the p21/WAF-1 and mdm2 genes after high-dose UV irradiation: p53-dependent and p53-independent regulation of the mdm2 gene. Mol. Med. 3: 441–451.
   PubMed Web of Science ®Google Scholar
• Wu, X., J. H. Bayle, D. Olson, and A. J. Levine 1993. The p53-mdm-2 autoregulatory feedback loop. Genes Dev. 7: 1126–1132.
   PubMed Web of Science ®Google Scholar